Home / Therapies / GLP-1 Agonist Therapy Center (page 5)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Cardiovascular Benefits of Oral GLP-1RA in High-Risk Patients with Type 2 Diabetes

Jul 6, 2019 Cardiology, GLP-1 Agonist Therapy Center

Results from the recently published PIONEER trial series demonstrate the overall diabetic benefits of oral semaglutide, a novel GLP-1 receptor agonist.

Liraglutide for Youth with Type 2 Diabetes

Jun 29, 2019 GLP-1 Agonist Therapy Center, Pediatrics, Type 2 Diabetes

The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.

Oral Semaglutide vs Subcutaneous GLP-1RAs — ADA 2019

Jun 22, 2019 GLP-1 Agonist Therapy Center, Type 2 Diabetes

New research findings on oral semaglutide vs subcutaneous liraglutide.

Liraglutide Lowers Risk of Cardiovascular Events In Type 2 Diabetes

Dec 8, 2018 Articles, Cardiology, GLP-1 Agonist Therapy Center, Type 2 Diabetes

GLP-1 treatment benefits patients on statins and with varying LDL levels.

GLP-1/GIP Drug Shows Promise in Reducing A1c and Reducing Weight

Nov 10, 2018 Articles, GLP-1 Agonist Therapy Center

New combination drug has better efficacy in glucose control and weight loss than when taken separately.

Oral Semaglutide Shows Promise in HbA1c Reduction and Weight Loss

Nov 3, 2018 Articles, GLP-1 Agonist Therapy Center, Obesity, Type 2 Diabetes

First oral GLP-1 agonist undergoing Phase 3 trials shows significant benefits managing type 2 diabetes.

Albiglutide’s Effect on Cardiovascular Outcomes in People with Type 2 Diabetes

Nov 3, 2018 Articles, Cardiology, GLP-1 Agonist Therapy Center, Type 2 Diabetes

Study looks at convenient once-weekly GLP-1 that can reduce chances of heart attacks and strokes.

GLP-1 Agonist Medications Chart

Nov 1, 2018 GLP-1 Agonist Therapy Center, Tools

This GLP-1 Agonist Medications Chart outlines the latest GLP-1 medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike. The chart is in PDF format. Use this link to download: GLP-1 Agonist Medications Chart